Eye Associates Of Shawnee Pa | |
15951 W 65th St, Shawnee, KS 66217 | |
(913) 268-9190 | |
(913) 268-2654 |
Full Name | Eye Associates Of Shawnee Pa |
---|---|
Type | Facility |
Speciality | Optometrist |
Location | 15951 W 65th St, Shawnee, Kansas |
Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316009111 | NPI | - | NPPES |
738029 | Other | KS | BLUE CROSS BLUE SHIELD OF KANSAS |
26236026 | Other | MO | BLUE CROSS BLUE SHIELD OF KANSAS CITY |
DO0466 | Other | KS | RR MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | (* (Not Available)) | Primary |
Provider Name | Vincent A Pennipede |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1437218484 PECOS PAC ID: 4789656950 Enrollment ID: I20050905000002 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | John T Davis |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1891861894 PECOS PAC ID: 3779555941 Enrollment ID: I20070810000794 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Mark Lynn Siefkes |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1285793786 PECOS PAC ID: 1456323492 Enrollment ID: I20070813000219 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Christina Annette Bartimus - Cottle |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1447326434 PECOS PAC ID: 0143292078 Enrollment ID: I20070813000254 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Andrea D Buchbaum |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1992954531 PECOS PAC ID: 3577743368 Enrollment ID: I20110210001177 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Madison M Ruelle |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1609280429 PECOS PAC ID: 8628296514 Enrollment ID: I20140908001042 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Jason L Green |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1952717662 PECOS PAC ID: 2466671482 Enrollment ID: I20140923002351 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Lisa A Muiller |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1659755239 PECOS PAC ID: 9436455003 Enrollment ID: I20160308000623 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Whitney L Pollock |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1033523832 PECOS PAC ID: 7517263916 Enrollment ID: I20160310002469 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Cassie N Baker |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1235554999 PECOS PAC ID: 3375812845 Enrollment ID: I20170627002731 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Andria N Demosthenous |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1558629923 PECOS PAC ID: 8628226420 Enrollment ID: I20180817002140 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Carrie R Turley |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1457597676 PECOS PAC ID: 5597928192 Enrollment ID: I20190624003042 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Provider Name | Tyrone A Diggs |
---|---|
Provider Type | Practitioner - Optometry |
Provider Identifiers | NPI Number: 1336890201 PECOS PAC ID: 4789076787 Enrollment ID: I20220125002581 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Eye Associates Of Shawnee Pa 10120 W 119th St, Overland Park, KS 66213 Ph: (913) 339-9090 | Eye Associates Of Shawnee Pa 15951 W 65th St, Shawnee, KS 66217 Ph: (913) 268-9190 |
News Archive
NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.
Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.
St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.
A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States - but, "lack of teamwork, negative culture and poor communication" will present barriers to patient safety in the future - according to a new survey commissioned by American International Group in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
› Verified 2 days ago
Clifford L. Holt, O.d.,p.a. Optometrist Medicare: Medicare Enrolled Practice Location: 6435 Nieman Rd, Shawnee, KS 66203 Phone: 913-631-6959 Fax: 913-631-5930 | |
Westglen Eyecare Pa Optometrist Medicare: Medicare Enrolled Practice Location: 16202 Midland Dr, Shawnee, KS 66217 Phone: 913-962-2010 Fax: 913-962-2013 | |
Dr. Seema Amin, O.DO Optometrist Medicare: Medicare Enrolled Practice Location: 14519 W 60th Ter, Shawnee, KS 66216 Phone: 913-940-1970 | |
Dr. Ryan Wineinger, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 7505 Quivira Rd, Shawnee, KS 66216 Phone: 913-631-0090 | |
Dr. Kinsey Rachel Honeyman, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5433 Roberts Street, Shawnee, KS 66226 Phone: 913-422-5200 Fax: 913-422-5218 | |
Latter Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 15700 Shawnee Mission Pkwy, Shawnee, KS 66217 Phone: 913-787-0196 | |
Dr. Andrea M. Beatty, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 16202 Midland Dr, Shawnee, KS 66217 Phone: 913-962-2010 Fax: 913-962-2013 |